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Sarcopenia, i.e., muscle loss is now a well-recognized complication of cirrhosis
and in cases of non-alcoholic fatty liver disease can contribute to accelerate liver
fibrosis leading to cirrhosis. Hence, it is imperative to study interventions which
targets to improve sarcopenia in cirrhosis.
AIM
To examine the relationship between interventions such nutritional
supplementation, exercise, combined life style intervention, testosterone
replacement and trans jugular intrahepatic portosystemic shunt (TIPS) to
improve muscle mass in cirrhosis.
METHODS
We search PubMed, EMBASE and Cochrane between June-August 2018, without
a limiting period and the types of articles (RCTs, clinical trial, comparative study)
in adult patients with sarcopenia and cirrhosis. The primary outcome of interest
was improvement in muscle mass, strength and physical function interventions
mentioned above. In the screening process, 154 full text articles were included in
the review and 129 studies were excluded.
RESULTS
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We identified 24 studies that met review inclusion criteria. The studies were
diverse in terms of the design, setting, interventions, and outcome measurements.
We performed only qualitative synthesis of evidence due to heterogeneity
amongst studies. Risk of bias was medium in most of the included studies and
low quality of evidence showed improvement in the muscle mass, strength and
physical function following aerobic exercise. 60% of the included studies on the
nutritional intervention, 100% of the studies on testosterone replacement in
hypogonadal men and trans-jugular portosystemic shunt were proved to be
effective in improving sarcopenia in cirrhosis.
CONCLUSION
Although the quality of evidence is low, the findings of our systematic review
suggest improvement in the sarcopenia in cirrhosis with exercise, nutritional
interventions, hormonal and TIPS interventions. High quality randomized
controlled trials needed to further strengthen these findings.
Key words: Sarcopenia; Cirrhosis; Treatment; Intervention; Nutrition; Therapy; Exercise;
Testosterone; Trans jugular intrahepatic portosystemic shunt
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Core tip: Sarcopenia is now a well-recognized complication of cirrhosis and in cases of
non-alcoholic fatty liver disease can contribute to accelerate liver fibrosis leading to
cirrhosis. Hence, it is imperative to study interventions which targets to improve
sarcopenia in cirrhosis. Aim of this systematic review of the literature was to examine
the relationship between interventions such nutritional supplementation, exercise,
combined life style intervention, testosterone replacement and trans jugular intrahepatic
portosystemic shunt to improve muscle mass in cirrhosis. We suggest improvement in
the sarcopenia in cirrhosis with exercise, nutritional interventions, hormonal and trans
jugular intrahepatic portosystemic shunt interventions.
Citation: Naseer M, Turse EP, Syed A, Dailey FE, Zatreh M, Tahan V. Interventions to





Sarcopenia, a term first coined by Irwin Rosenberg, drives its origin from the Greek
phrase  sarx  meaning  “flesh/muscle”  and  penia  meaning  “loss”[1].  Although  a
standard definition is  lacking,  sarcopenia  is  defined as  the  degenerative  loss  of
skeletal muscle mass that is involuntary and age related[2]. Sarcopenia resulting from
advance age is referred to as primary sarcopenia. This can begin as early as the 4th
decade of life and progresses in a linear fashion resulting in up to 50% loss of skeletal
muscle mass by the 8th decade of life. Sarcopenia caused by chronic conditions such
as liver cirrhosis or malignancy is referred to as secondary sarcopenia[3]. Cirrhosis is a
result of chronic liver injury cumulating in irreversible hepatocellular dysfunction,
cell death, vascular remodeling and fibrosis. Although liver transplantation can cure
this condition, it is not always a viable option for the majority of patients[4]. As such,
efforts  are  focused  on  preventing  and  controlling  complications  of  the  disease.
Sarcopenia in cirrhosis is a cause of increase morbidity and mortality with recent
studies demonstrating sarcopenia as an independent predictor of poor survival in
cirrhotic patients with or without hepatocellular cancer[5,6].  In the USA sarcopenia
secondary to cirrhosis affects over 300000 people and is associated with increased cost
of treatment, length of stay in hospital and, pre and post-transplant mortality[7-16].
The  stigmata  of  cirrhosis  is  widely  understood  and  includes  hepatocellular
carcinoma (3%-5%),  ascites  (5%-10%),  variceal  bleeding  (10%-15%),  and hepatic
encephalopathy (62.4%)[5,6].  Sarcopenia,  despite  being  a  prevalent  feature  of  the
disease,  is  not  as  readily  associated  with  cirrhosis.  Malnutrition  resulting  in
sarcopenia  is  one  of  the  most  frequent  complications  in  patient  with  cirrhosis;
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adversely affecting other complications, survival, quality of life, and outcomes after
liver transplantation[7-16]. Patients with cirrhosis develop protein energy malnutrition
at a rate of 25.1%-65.6%[3,17-19]. The prevalence of sarcopenia also is noted to have a
similar  distribution (30%-70%).  Patients  with cirrhosis  also have severe exercise
intolerance which further contributes to malnutrition and ultimately sarcopenia.
According to the findings of a recent systematic review, a mean peak VO2  of 17.4
mL/kg per min was reported in patients with cirrhosis awaiting liver transplantation.
For comparison this is  a value typically found in female aged 80–89 year having
sedentary life style[20].
A vast disparity in prevalence of secondary sarcopenia from cirrhosis is seen due to
a lack of a standard definition, varying patient baseline characteristics, and diversity
in the cause and severity of liver disease among studies[21]. Currently due to lack of
studies, the economic data on sarcopenia is poor[22]. The direct cost of sarcopenia in the
USA was estimated to be $18.5 billion. The primary factors influencing this cost were
hospitalization, nursing home admissions, and home healthcare expenditures. This
value represents 1.5% of total healthcare expenditure in the USA[23]. The indirect costs
of  sarcopenia  are  not  considered  when calculating  the  $18.5  billion  dollars  and
sarcopenia likely costs the USA far more. These costs include disability resulting from
sarcopenia, increased risk of comorbidities, osteoporosis[24],  obesity[25],  and type II
diabetes[26].  All  in  all,  the  true  cost  of  sarcopenia  is  sure  to  be  staggering.  This
systematic review will provide an in-depth review of current treatment modalities for
combatting sarcopenia in patients with cirrhosis.
Interventions  such  as  exercise,  improved nutrition,  hormonal  replacement  in
hypogonadal men and trans jugular intrahepatic portosystemic shuts (TIPS) have
been evaluated in various randomized and non-randomized studies. The aim of this
study  was  to  perform  a  systematic  review  of  the  studies  that  focuses  on  the




This systematic review was registered at the international prospective register of
systematic reviews platform (PROSPERO, registration number: CRD42018109320).
This  study followed the  recommendations  of  the  Preferred  Reporting  Items  for
Systematic Reviews and Meta-Analyses[27].
Eligibility
Studies  that  reported  a  relationship  between  interventions  such  as  exercise,
nutrition/diet, TIPS and testosterone and a measure of skeletal muscle mass and/or
physical  function  in  cirrhotic  populations  were  deemed  eligible.  Studies  were
included in the systematic review when they met following inclusion criteria: (1)
Randomized clinical trials (RCTs), quasi experimental, cohort and case control studies
published in peer reviewed journal; (2) Focused on single or combined intervention
such as exercise, nutrition/diet, TIPS or testosterone on adult cirrhotic patient ≥ 18
years; and (3) Outcome measure i.e., sarcopenia which was assessed by one or more
physical  function  (anthropometry,  Bioelectric  impedance  analysis,  computed
tomography (CT), ultrasound measurement of muscle thickness or assessment of
physical function by using 6 mins walk test or peak VO2 measurement).
After preliminary review of title and abstract we excluded conference abstracts,
case reports, series, editorials and articles that were not in English language. Studies
evaluating the effect of these interventions on outcomes other than sarcopenia were
also excluded.
Study search and selection
We search PubMed, EMBASE and Cochrane between June-August 2018, without a
limiting period and the types of articles (RCTs, clinical trial,  comparative study).
Following  set  of  keywords  were  used  for  the  search  strategy:  “Muscular
Atrophy"[Mesh] OR "Sarcopenia"[Mesh] OR (“Atrophic muscular disorders” OR
“Muscle atrophy” OR “Muscle degeneration” OR “Muscle fiber atrophy” OR “Muscle
fiber degeneration” OR “Muscle wasting” OR “Muscular wasting” OR “Muscular
atrophy” OR “Muscular atrophies” OR “Muscular degeneration” OR Myoatrophy OR
Myatrophy OR Myophagism OR Myodegeneration OR Myophagism OR Sarcopenia)
AND ("Liver Cirrhosis"[Mesh]) OR (Cirrhosis OR Cirrhoses OR “Liver fibrosis” OR
“Liver  fibroses”).  Filters  were  used  to  limit  the  search  to  those  in  the  English
language. Eligible studies were selected after reading title and abstract. Full text of
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article was read when subject or outcomes of interest were not clear.
Data collection process and variables
Data was collected by two independent investigators for the following variables:
author, type of the study, year of the study conducted, setting, characteristics of the
study participants, sample size, study design, intervention, and changes in the muscle
mass/ physical function following intervention. Third reviewer was involved to solve
a disagreement in the findings of two reviewers and solved by discussion.
Assessment of risk of bias
Risk of bias was assessed by two independent reviewers using standard assessment
tool recommended by Centre for Reviews and Dissemination (CRD) for non RCT
studies including case control and pre-post intervention. The CRD tool has a set of ten
criteria by which to evaluate risk of bias: study setting, design, population, exposure
(exercise,  nutrition,  testosterone/TIPS),  reliability  of  outcome  measurements
(sarcopenia) obtained, adjustment for confounders,  blinding, losses to follow-up,
information on non-participants and information on analyses. Studies with total score
of  -9  to  -3  were  classified  as  “high  risk”.  Studies  with  score  of  -2  to  +3  were
categorized as “medium risk”; or “low risk” of bias if the was +4 to +10[27].
For randomized controlled trial,  the risk of  bias was assessed using Cochrane
Collaboration’s  tool.  The  tool  assessed  studies  based  on  randomized  sequence
generation, treatment allocation concealment, blinding, completeness of the outcome
data, and selective outcome reporting and other sources of bias[28].
RESULTS
Search results
Preliminary search yielded 1673 articles. After removal of duplicate (n = 236 articles),
1437 titles and abstract were screened to determine their eligibility to be included in
the systematic review. Following careful review of titles and abstract we excluded
1283 articles. Total of 154 articles were assessed fully by 2 reviewers out of which 130
abstracts were excluded as they were not meeting inclusion criteria. Finally, we found
24 full texts articles to be eligible and were included in the review (Figure 1).
Characteristics of the studies
Out of 24 studies included in the systematic review, 3 studies were case control[30,38,49],
8 studies were non RCT (pre-post intervention/ quasi experimental)[37,40,45-48,50,51] and 13
were  randomized controlled  trial[29,31-36,39,41-44,52].  All  the  studies  were  done  in  the
hospital setting and the sample sizes ranged from 6 to 174 participants. In almost all
studies,  liver cirrhosis was diagnosed with documented histology,  confirmed by
laboratory data sonographic and endoscopic evidence of portal hypertension. 9 out of
24  studies  had  over  50  participants.  Seven  studies  were  done  in  patients  with
decompensated cirrhosis. In 17 studies Child-Turcotte-Pugh score ranged between 6-
9. Most of the studies (n = 22) had participants whose mean age ranged between 40
and 60 years, with only two studies enrolled participants above 70 years. Male to
female ratio was 1.5:1 and mean BMI of the study participants was 26.  Study by
Dupont et al[34] was done exclusively in patients with alcoholic liver cirrhosis without
current  evidence of  alcoholic  hepatitis  and Nakaya et  al[31]  enrolled patient  with
cirrhosis  secondary to  chronic  hepatitis  C infection.  Though most  of  the studies
excluded patients with current symptoms of hepatic encephalopathy, ascites, variceal
bleeding from esophageal varices, Maharshi et al[35] evaluated the effect of nutritional
supplement in cirrhotic patient with minimal hepatic encephalopathy.
In most of the included studies sarcopenia was assessed using muscle mass, and
muscle strength via skin fold thickness, hand grip muscle circumference, lean and fat
muscle mass using anthropometric measurement and bioelectric impedance analysis.
In  four  studies  muscle  and  fat  mass  was  measured  using  imaging  (CT  scan  or
ultrasound).  Physical  performance i.e.,  functional  capacity used as  a  measure of
sarcopenia is six studies.
Study findings
The synthesis of study findings is presented by intervention in the following order:
nutritional intervention, exercise, combined exercise and nutrition, testosterone and
TIPS (Tables 1-5)
Nutritional interventions
Total  of  10  studies  published  between  2000-2018  on  nutritional  intervention  to
improve  sarcopenia  in  cirrhosis  were  included.  Seven  out  of  ten  studies  were
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Figure 1
Figure 1  Preferred reporting items for systematic reviews and meta-analyses diagram of interventions to improve sarcopenia in cirrhosis.
randomized controlled trials, 2 were case control and 1 was longitudinal (pre-post
intervention study).  Four of  the studies  were conducted in Japan,  four from the
Europe, one study was conducted in Mexico, and one was from India. Nutritional
intervention duration ranged from 6 to 56 wk and the sample size ranged from 21 to
174 patients with cirrhosis. Nine studies were done in compensated cirrhosis and one
involved  decompensated  cirrhotic  patients.  In  seven  of  the  included  studies
supplementation with branched chain amino acids (BCAA) was used as intervention
with regular diet, or a high protein and high fiber diet or with late evening snack
(LES). Study conducted by Yamanaka-Okumura et al[30] investigated the effect of LES
with meals in patients with cirrhosis. Overall, nutritional interventions with BCAA
were found to be effective in 60% of the studies. However, four studies showed no
significant changes in the sarcopenia measured by anthropometric analysis following
nutritional interventions.
Exercise interventions
Details of the studies focused on the exercise intervention are presented in Table 2.
Out of five studies four were randomized control trials were conducted between 2014-
2018. 2 studies were done in Canada, one in Mexico, and 2 in Europe. Duration of
exercise intervention was lasted between 8 to 14 wk. Supervised physical exercise was
used as intervention in four of the included studies. All studies showed significant
improvement in muscle mass, physical function and muscle strength post exercise
intervention.
Combined interventions
Four studies  based on combined exercise  and nutritional  supplementation were
included in the systematic review. Three studies used pre-post intervention (quasi
experimental) study design to evaluate the effect of combined life style intervention
such exercise and nutrition on sarcopenia (details are presented in Table 3).  Two
studies were done in Japan and two in Spain. Interventions ranged from 12 to 52 wk
and includes BCAA supplementation either with home based or supervised exercise.
All these studies reported significant improvement in muscle mass, muscle strength
and physical function. However, Berzigotti et al[47] reported no significant changes in
the lean muscle mass following 16 wk of life style intervention which include reduce
calorie intake of 500-1000 Kcal/d along with 60 min session of moderate supervised
exercise.
TIPS
Efficacy of TIPS in the treatment of sarcopenia was assessed in the four studies. All
these studies were done in decompensated cirrhotic patients.  Three studies were
conducted in Europe while one was done in USA. Sample size in the studies ranged
from 21-132 patients. Most of the studies utilized pre-post intervention study design
and reported significant improvement in sarcopenia following TIPS. However, Plauth
et al[48] reported no change in the resting energy expenditure and fat mass.
Testosterone
Two studies  (one  RCT and one  non RCT pre-post  intervention)  on  the  effect  of
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testosterone on sarcopenia in cirrhosis met eligibility criteria. These studies were done
in Turkey and Australia. Study by Yurci et al[51], enrolled 16 males with compensated
cirrhosis with mean BMI of 27. Study lasted for 6 mo and showed significant increase
in muscle strength. Similar results were reported by a large randomized controlled
trial in 2016 conducted by Sinclair et al[52].
Risk of bias
Detailed description of the risk of bias in randomized and non-randomized (pre-post
intervention studies and case-control studies) is presented in Tables 6 and 7.
DISCUSSION
It has been established that sarcopenia has an independent association with adverse
outcomes in patients with cirrhosis which includes increased morbidity, mortality and
cost of recurrent hospitalization from its complications[53]. In this systematic review we
assessed and qualitatively analyzed the evidence regarding relationship between
interventions such as  nutritional  supplementation,  exercise,  combined life  style,
hormonal replacement with testosterone and trans-jugular portosystemic shunt to
improve muscle mass, strength and physical function in patients with established
cirrhosis. Few of the included studies also showed improved health related quality of
life, decreased hepatic venous pressure gradient (HVPG), improvement in hepatic
encephalopathy and recurrent ascites following these interventions[32,33,47].  Several
systematic  reviews  have  been  published  which  were  aimed  to  establish  the
relationship between exercise and diet quality with sarcopenia in older adults[54,55].
However, this is the first attempt to systematically review the published literature on
interventions to improve sarcopenia in cirrhotic patients.
There  is  strong  body  of  evidence  that  BCAA  (leucine,  isoleucine  and  valine)
supplementation  improves  protein  synthesis,  glucose  and  lipid  metabolism,
hepatocyte proliferation, decrease oxidative stress in the hepatocytes and ameliorate
insulin resistance in patients with liver cirrhosis[56]. However, studies published by
Yamanaka-Okumara et al[30] showed no significant changes in the muscle mass and
strength following BCAA supplementation with  LES,  potentially  due to  shorter
duration of the intervention (1 wk only). Similarly, Nakaya et al[31], Sorrentino et al[33]
and Dupont et al[34], did not showed improvement in the anthropometric measurement
following LES with BCAA supplementation possibly due to small sample size and
shorter duration of intervention. Timing of BCAA administration, dose and whether
BCAA was  supplemented  with  nutritional  education  could  be  another  possible
explanation for these studies not showing significant improvement in muscle mass.
Existing data on the effects of exercise in cirrhosis is limited and controversial
especially in patients with decompensated cirrhosis. It has been reported that acute
exercise can induce oxidative stress and proinflammatory cytokines synthesis, which
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CPET: Cardiopulmonary exercise testing; CSA: Cross sectional area; BMI: Body mass index.
can lead to liver damage, portal hypertension and development of complications[57]. A
case series of 8 patients with cirrhosis published in 1996 by García-Pagàn et  al[58]
reported significant worsening of HVPG following moderate exercise training which
could  lead  to  increased  risk  of  variceal  bleeding.  In  contrary,  recent  pre-post
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AT: Anaerobic threshold; IMAC: Intramuscular adipose tissue content; BMI: Body mass index.
intervention study by Berzigotti et al[47] on combined life style intervention reported
improvement in HVPG following 16 wk of life style intervention. However, these
patients were on non-selective beta blockers for primary prophylaxis  of  variceal
hemorrhage. Evidence is lacking on the effect of anaerobic-high intensity interval
exercise and resistance training in cirrhotic adults with sarcopenia. Most of the studies
included  in  this  review,  focused  on  aerobic  exercise  intervention.  A  recently
published abstract of randomized control trial by Aamann et al[59], not included in this
review,  evaluated the  effect  of  resistance  training  with  adequate  protein  intake
showed significant increase in muscle mass, strength and quality of life scores. Similar
to nutrition interventions, differences in the type of exercises, in the duration of the
sessions, in the number of patients per session, supervised vs home based exercise
found to effect outcomes in cirrhotic patients.
Based  on  this  review,  early  supervised  exercise  intervention  with  BCAA
supplementation can be considered for patients with cirrhosis and sarcopenia. While
BCAA approximately costs $20-50 for 30 servings it is relatively cost effective given
that 60% of the studies showed improvement of patient’s sarcopenia[60]. TIPS cannot
be concluded regarding recommendations given that the studies had small numbers
of patients and one of four studies did not show improvement. Testosterone while it
showed improvement in the two studies used for secondary sarcopenia from cirrhosis
should be used with caution given its known side effects of increased cancer risks
especially in this population[30].  However,  hypogonadism due to cirrhosis is well
understood. Patients with low testosterone and increased sarcopenia may thus benefit
from supplementation and careful clinical screening and monitoring for side effects of
supplementation.
The 24 studies included in this review highlight several strengths and limitations.
Strengths of these studies include that they were conducted in patients with both
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TBP:  Total  body  protein;  REE:  Resting  energy  expenditure;  FFA:  Free  fatty  acid;  CT:  Computed  tomography;  TIPS:  Trans  jugular  intrahepatic
portosystemic shunt; BMI: Body mass index.
compensated  (mainly  exercise,  nutritional  supplementation  and  life  style
interventions) and decompensated cirrhosis (mainly TIPS). Additionally, these studies
were conducted in  many countries  across  the world capturing a  diverse  patient
population and diverse causation for cirrhosis (chronic hepatitis C infection, alcoholic
cirrhosis, autoimmune hepatitis and primary biliary cirrhosis).
Limitations  of  these  studies  include  that  less  than  half  had  large  patient
populations with more than 50 patients. Moreover, almost half were non-randomized
trials. Obviously, studies that are descriptive cannot determine a cause and effect
relationship and studies that are retrospective and quasi-experimental allow for bias
and confounders as mentioned above. Also, the included studies were diverse in
terms of  study designs,  interventions,  and duration of  intervention,  follow ups,
characteristics of the patients enrolled, measurement of sarcopenia and the statistical
methods to control confounding variables. These inconsistencies in the methodology
of these studies contribute to the heterogeneity of the results. The level of evidence
according to GRADE criteria is very low or low due to marked heterogeneity of these
studies.  Moreover,  there  is  only  one  study  that  showed  improved  mortality  or
morbidity  by  intervention  and some of  the  rest  of  included studies  just  proved
improvement of sarcopenia. Therefore, the clinical significance of the improvement of
sarcopenia in cirrhotic patients remains unknown.
Future studies should include prospective multi-treatment modality approach i.e.,
exercise plus BCAA supplementation with specific dosage requirements in a large
patient  population including both  those  with  compensated and decompensated
cirrhosis.  Another  interesting  study  would  be  performing  TIPS  in  patients  as
sarcopenia as an indication rather than bleeding from varices, refractory ascites or
hydrothorax. This study would be significant because if it resulted in improvement of
sarcopenia could be an early intervention for pre and post-transplant improvement of
morbidity  and  mortality  in  these  patients.  Yet,  increased  likelihood  of  hepatic
encephalopathy is always a concern in these individuals. Overall, these 24 studies
highlight the need for improving patient’s secondary sarcopenia from cirrhosis to
improve their outcomes and provide guidance for future possible studies.
WJCC https://www.wjgnet.com January 26, 2019 Volume 7 Issue 2
Naseer M et al. Sarcopenia in cirrhosis
165
















































APLM: Appendicular lean mass; BMI: Body mass index.
Table 6  Summary of scoring results in terms of risk of bias (low, medium or high) of all studies included in the review
Ref.
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Hiraoka et
al[46], 2017
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Nishida et
al[45], 2016






































+1 +1 0 +1 0 0 +1 +1 +1 -1 5 = low risk
Total score -9 to -3 = high risk of bias; -2 to +3 = medium risk of bias; +4 to +10 = low risk of bias.
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ARTICLE HIGHLIGHTS
Research background
Sarcopenia, i.e., muscle loss is now a well-recognized complication of cirrhosis; and in cases of
non-alcoholic fatty liver disease, it can contribute to accelerate liver fibrosis leading to cirrhosis.
Research motivation
It is imperative to study interventions which targets to improve sarcopenia in cirrhosis.
Research objectives
Aim  of  this  systematic  review  of  the  literature  was  to  examine  the  relationship  between
interventions and trans jugular intrahepatic portosystemic shunt (TIPS) to improve muscle mass
in cirrhosis.
Research methods
We search PubMed, EMBASE and Cochrane between June-August 2018, without a limiting
period and the types of articles in adult patients with sarcopenia and cirrhosis. The primary
outcome  of  interest  was  improvement  in  muscle  mass,  strength  and  physical  function
interventions mentioned above.
Research results
Twenty four studies that met review inclusion criteria were identified. The studies were diverse
in terms of the design, setting, interventions, and outcome measurements. Only qualitative
synthesis of evidence due to heterogeneity amongst studies was performed. Risk of bias was
medium in most of the included studies, and low quality of evidence showed improvement in
the muscle mass, strength and physical function following aerobic exercise. There are 60% of the
included studies on the nutritional intervention, 100% of the studies on testosterone replacement
in hypogonadal men and trans-jugular portosystemic shunt were proved to be effective in
improving sarcopenia in cirrhosis.
Research conclusions
Although  the  quality  of  evidence  is  low,  the  findings  of  this  systematic  review  suggest
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improvement in the sarcopenia in cirrhosis with exercise, nutritional interventions, hormonal
and TIPS interventions.
Research perspectives
High quality randomized controlled trials are needed to further strengthen these findings.
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